Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study

Journal Title: 
Blood Advances
Primary Author: 
Mitani K
Author(s): 
Mitani K, Lee JW, Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Murotani K, Shimizu M, Matsuda A, Ozawa K, Nakao S
Original Publication Date: 
Friday, December 22, 2023
Bone Marrow Disease(s):